# Astellas Pharma Inc. announced the first results from the open-label extension trial of the Phase 3 GATHER2 study.

*biotech · news · 2025-10-20 · MarketScreener*

## Key points

- IZERVAY continued to reduce GA lesion growth for up to 3.5 years in treated patients.
- Earlier initiation of IZERVAY treatment showed greater retinal tissue protection in GA patients.
- No cases of retinal vasculitis or occlusive vasculitis were reported during the long-term extension trial.
- Real-world U.S. data confirmed low discontinuation rates and no new safety signals for IZERVAY.

**Companies:** Astellas Pharma Inc.
**Countries:** United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/astellas-pharma-inc-announces-first-results-from-the-open-label-extension-trial-of-the-phase-3-gath-ce7d5ad2d888fe27)

---

Canonical: https://newsio.io/n/de6d6641-306f-4f69-8aa7-c8b54b687831/astellas-pharma-inc-announced-the-first-results-from-the-open-label-extension-tr
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works